Ignite Creation Date:
2025-12-24 @ 4:07 PM
Ignite Modification Date:
2026-02-25 @ 6:35 PM
Study NCT ID:
NCT03026166
Status:
TERMINATED
Last Update Posted:
2020-07-17
First Post:
2017-01-18
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-03-30
Start Date Type:
ACTUAL
Primary Completion Date:
2019-07-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-07-03
Completion Date Type:
ACTUAL
First Submit Date:
2017-01-18
First Submit QC Date:
None
Study First Post Date:
2017-01-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-06-12
Results First Submit QC Date:
None
Results First Post Date:
2020-07-01
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-07-01
Last Update Post Date:
2020-07-17
Last Update Post Date Type:
ACTUAL